Please select the option that best describes you:
Topics:
Hematologic Malignancies • Medical Oncology • Leukemia • Internal Medicine • CLL • Hematology
What is your approach to re-challenging BTK inhibitors for a patient who has had intolerance to several different agents?
Patient developed atrial fibrillation on Ibrutinib, severe fatigue and intolerance to Zanubrutinib and a maculopapular rash (grade 2) on Acalabrutinib
Answer from: Medical Oncologist at Academic Institution
This is a great question, and the answer is that I probably would not rechallenge with a BTK inhibitor. Many patients who develop an intolerance to a BTKi can remain on the drug with supportive care for the toxicity and/or dose reduction, which is not always effective. If someone truly had an intole...
Sign in or Register to read more